This activity is supported by an independent educational grant from |
FacultyEdith A. Perez, MD (Chairperson)
Mayo Clinic
Dr. Perez is the director of the Breast Clinic and the Cancer Clinical Study Unit at Mayo Clinic in Jacksonville, Florida, as well as a member of the Mayo Clinic Women’s Cancer Program Steering Committee. Dr. Perez received her medical degree from the University of Puerto Rico School of Medicine in San Juan, and completed a residency in internal medicine at the Loma Linda University Medical Center in California. She has developed and is involved in a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. She also has recently developed studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has written more than 150 research articles in journals and books and is a frequent invited lecturer at national and international meetings each year. Edith A. Perez, MD, reported no areas of conflict. Clifford A. Hudis, MD
Memorial Sloan-Kettering Cancer Center
Dr. Hudis is chief of the breast cancer medicine service and attending physician at Memorial Sloan- Kettering Cancer Center in New York City. He also is also a professor of medicine at the Weill Medical College of Cornell University. He received his doctor of medicine from the Medical College of Pennsylvania, Philadelphia. His primary research interests include chemotherapy development, hormone therapy, novel targeted therapeutics, and supportive care. Dr. Hudis has also served on the editorial boards of several medical journals and is a member of the breast cancer committees of the Radiation Therapy Oncology Group and National Comprehensive Cancer Network. Clifford Hudis, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Amgen, Inc., Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer, Inc. and sanofi-aventis U.S.; Contracted Research, Kosan BioSciences. Jose Baselga, MD
Vall d'Hebron University Hospital, Barcelona, Spain
Dr. Baselga is chairman of the Medical Oncology Service at the Vall d’Hebron University Hospital in Barcelona, Spain. He obtained his medical degree from the Universidad Autonoma of Barcelona and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center in New York City. His research interests focus on clinical breast cancer and translational and early clinical research of growth factor receptors as well as downstream molecules as targets for breast cancer therapy. Dr. Baselga has also been involved in the clinical development of several novel agents. Jose Baselga, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Exelixis, Inc., Novartis Pharmaceuticals Corporation, and Merck & Co., Inc.; Ownership Interest, GlaxoSmithKline plc.
Linda T. Vahdat, MD
Weill Medical College of Cornell University Dr. Vahdat is associate professor of clinical medicine and director of the Breast Cancer Center at Weill Cornell Medical College in New York City. She attended medical school and completed her training in internal medicine at Mount Sinai School of Medicine in New York City. Dr. Vahdat completed a fellowship in hematology and medical oncology at Memorial Sloan-Kettering Cancer Center. She is involved in the design and conduct of phase I through III clinical trials in breast cancer and has expertise in peripheral neuropathy and the evaluation of new agents. Dr. Vahdat serves as associate editor for the American Society of Clinical Oncology Web site, People Living With Cancer (PLWC.org). Linda T.Vahdat, MD, reported no areas of conflict.
Accreditation StatementsThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of PIM and IMER. PIM is accredited by the ACCME to provide continuing medical education for physicians. PIM designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Safeguards Against Commercial BiasIMER and PIM affirm that the content and format of its CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER and PIM employ several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CME activities jointly-sponsored by IMER and PIM to ensure adherence to ACCME’s content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review your materials: 1. Fair balance
3. Appropriateness of patient care recommendations made to learners Privacy PolicyWhen you participate in a CME activity provided by The Postgraduate Institute of Medicine (“PIM” or “we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways: We use the Information to grade your posttest and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the Information to that company for that purpose only. For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey. We may use the Information to invite you to participate in other CME activities that PIM or its affiliates may offer. On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in CME (ie, who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title, and affiliation but we will request in writing that the supporter not contact you directly for any purpose. If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business. Any changes to our privacy policy will be posted on our Web site.
Method of ParticipationThere are no fees for participating and receiving nursing contact hours for this activity. During the period January, 2009 through December, 2009, participants must: (1) read the learning objectives and faculty disclosures; (2) study the educational activity; (3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; (4) complete the evaluation form; and (5) mail or fax the evaluation form and posttest to IMER. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks. MediaWeb site
|
|||||||||||
